In recent years, the environment and infrastructure available for conducting clinical trials in Southeast Asia have improved. The region has attracted an increasing number of drug development trials from US and European sponsors. Lately, some Japanese pharmaceutical companies have begun to conduct Pan-Asian multicenter trials involving some Southeast Asian countries. It is expected that the globalization movement in drug development and the emerging trend of Pan-Asian trials will create increasing demands on Southeast Asian sites and fuel the growth of the clinical trial market in the region.
